Sir,
Fever is one of the most challenging problems in systemic lupus erythematosus (SLE) and the following example may be paradigmatical. A 53year-old woman diagnosed with SLE (2001: fever, arthritis, subacute cutaneous lupus, anti-dsDNA, ANA and anti-Ro positivity) with ongoing therapy with hydroxychloroquine (200 mg/day) and low dose prednisone (2.5 mg/day) in October 2009 presented with fever (up to 38 C) and arthromyalgias not responsive to prednisone increase up to 25 mg/day and broad-spectrum antibiotics treatment. When she was admitted to our division (December 2009), we first empirically started with levoxacin (500 mg/day, intravenous (i.v.)). Considering fever persistence, signs of disease activity (anti-dsDNA and direct Coombs' test positivity, C3 and C4 reduction, leukopenia) and the negativity of procalcitonin 1 and various cultures and serologies performed, we started prednisolone (40 mg/day, i.v.), again without improvement. Subsequently, because herpesvirus 6 (HHV-6) DNA was detectable in blood (467,600 copies/ml), ganciclovir (250 mg, twice a day) was started. However, after one week of antiviral therapy, viral load was still high (529,000 copies/ml), fever and arthromyalgias persisted, and cutaneous lesions suggestive of subacute cutaneous lupus appeared on the left cheek. On this basis chromosomally integrated HHV-6 (CIHHV-6) was first hypothesized and then confirmed by hair follicle HHV-6 DNA detection (92,680 HHV-6 DNA copies/100,000 cells). Ganciclovir was discontinued and three pulses of methylprednisolone (1 g, i.v.) were given, with subsequent tapering and methotrexate 10 mg/week was also started. Fever disappeared and the patient progressively improved. Up to the present there are no signs of SLE activity (SELENA-SLEDAI score 0), prednisone has been tapered to 2.5 mg on alternate days, weekly methotrexate is ongoing and a high copy number of HHV-6 (547,100 copies/ml) is still detectable in whole blood.
HHV-6, which comprises HHV-6 A and HHV-6B, is the only human virus able to integrate into chromosomes with clinical relevance; in fact, besides HHV-6, only endogenous retroviruses are known to be integrated in the host's germline genome. However, differently from HHV-6, endogenous retroviral sequences are considered evolutionary relics, being incomplete and lacking replicative competence. The chromosomal integration of HHV-6 DNA (CIHHV-6) led to high HHV-6 DNA copy levels in the blood, which may be incorrectly interpreted as 'active' infection. In these cases, unnecessary treatments might be performed and further evaluations of the true underlying aetiology of the clinical illness may be postponed. 2 Moreover, although HHV-6 reactivation has been reported in experimental settings, 3 up to now there are no cases of viral reactivation in humans with CIHHV-6, so antiviral prophylaxis and preemptive therapy is not recommended. CIHHV-6 is estimated to occur in about 0.8% of the general population and it has been described as a potential problem in both haematopoietic cell and solid organ transplantation. 1, 4 Up to now, CIHHV-6 has not been described in autoimmune diseases in general or in SLE in particular. In conclusion, although the direct identification of the pathogens is obviously the best way in diagnosis to differentiate between SLE and infection fever, the exception to the rule always exists, as this case indicates. When we attempt pathogen identification in SLE patients with fever, conditions such as CIHHV-6 should be taken into account in order to avoid unnecessary antiviral treatment and to identify and manage the right cause of fever.
